Cardiac hormones are c-Jun-N-Terminal Kinase 2-inhibiting peptides
Lane, Meghan L.
Frost, Chelsea D.
Skelton, William P.
Vesely, David L.
MetadataShow full item record
Lane M.L., Santana O., Frost C.D., Guerrero J., Skelton M., et al. 2012. "Cardiac hormones are c-Jun-N-terminal kinase 2-inhibiting peptides". Anticancer Research. 32 (3): 721-725
Background: Four cardiac peptide hormones, namely vessel dilator, long-acting natriuretic peptide (LANP), kaliuretic peptide, and atrial natriuretic peptide (ANP) have anticancer effects. Materials and Methods: The effects of these four cardiac hormones on human c-Jun-N-terminal kinase 2 (JNK2) were examined in human small cell lung cancer and human prostate cancer cells. Results: Vessel dilator, LANP, kaliuretic peptide and ANP maximally reduced expression of JNK2 by 89%, 56%, 45%, and 28%, respectively (each at p<0.0001) in human small cell lung cancer cells. In human prostate adenocarcinoma cells, JNK2 was maximally decreased 76%, 56%, 45%, (each at p<0.0001), and 28% (p<0.01) secondary to vessel dilator, LANP, kaliuretic peptide and ANP, respectively. Conclusion: These results indicate that four cardiac hormones are significant inhibitors (by up to 89%) of JNK2 in human small cell lung cancer cells and up to 76% in human prostate adenocarcinoma cells as part of their anticancer mechanism(s) of action.
Full text of this article is not available in SOAR.
- BIO Faculty Publications